Terry Pearson
Technik-/Wissenschafts-/F&E-Leiter bei Siscapa Assay Technologies, Inc.
Profil
Terry W.
Pearson is currently serving as a Director at CAVA Healthcare, Inc., Director at Science Council of British Columbia, Director at Eyam Vaccines & Immunotherapeutics Ltd., and Chief Scientific Officer at Siscapa Assay Technologies, Inc. Previously, he held positions as a Director at Marker Therapeutics, Inc., Independent Director at biOasis Technologies, Inc., Independent Director at Nevis Brands, Inc., Staff Scientist-Cell Biology Division at the University of British Columbia, Professor at the University of Victoria, and Trustee at The Terry Fox Foundation.
He obtained his undergraduate and doctorate degrees from the University of British Columbia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
inf% | 18.10.2023 | 100 000 ( inf% ) | - $ | Heute |
Aktive Positionen von Terry Pearson
| Unternehmen | Position | Beginn |
|---|---|---|
| Science Council of British Columbia | Direktor/Vorstandsmitglied | 01.09.2010 |
CAVA Healthcare, Inc.
 CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Direktor/Vorstandsmitglied | - |
Siscapa Assay Technologies, Inc.
 Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Eyam Vaccines & Immunotherapeutics Ltd. | Direktor/Vorstandsmitglied | 10.01.2022 |
Ehemalige bekannte Positionen von Terry Pearson
| Unternehmen | Position | Ende |
|---|---|---|
| BIOASIS TECHNOLOGIES INC. | Direktor/Vorstandsmitglied | 21.09.2017 |
| MARKER THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 05.12.2005 |
| University of British Columbia | Corporate Officer/Principal | - |
| NEVIS BRANDS INC. | Direktor/Vorstandsmitglied | - |
| University of Victoria | Corporate Officer/Principal | - |
Ausbildung von Terry Pearson
| University of British Columbia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| NEVIS BRANDS INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Siscapa Assay Technologies, Inc.
Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Health Technology |
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Consumer Non-Durables |
| The Terry Fox Foundation | |
| Science Council of British Columbia | |
| Eyam Vaccines & Immunotherapeutics Ltd. |
